Zelluna IDMC clears continued enrolment in ZIMA-101 trial after initial safety review

• Zelluna on Aug. 17, 2026 received an IDMC recommendation to continue enrolment in its first-in-human ZIMA-101 study.
• Initial safety data have already been reviewed; the first patient completed the first treatment cycle without serious safety issues.
• The committee cleared recruitment of two additional patients at the current starting dose level.
• Management expects more clinical data to be presented in the future as enrolment continues and follow-up progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170711OMX_____CNEWS_EN_GNW1001257939_en) on August 17, 2026, and is solely responsible for the information contained therein.